AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypesMinke A.E. Rab, Richard van Wijk, Brigitte A. van Oirschot et al.|Haematologica|2020Cited by 81
Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History StudyEduard J. van Beers, Rachael F. Grace, Stephanie van Straaten et al.|Haematologica|2018Cited by 61
Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiencyStephanie van Straaten, Richard van Wijk, Wouter W. van Solinge et al.|Haematologica|2017Cited by 59
Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapyMinke A.E. Rab, Richard van Wijk, Jennifer Bos et al.|Blood|2021Cited by 46
Decreased Activity and Stability of Pyruvate Kinase in Hereditary Hemolytic Anemia: A Potential Target for Therapy By AG-348 (Mitapivat), an Allosteric Activator of Red Blood Cell Pyruvate KinaseMinke A.E. Rab, Richard van Wijk, Brigitte A. van Oirschot et al.|Blood|2019Cited by 18